ANNUAL SCIENTIFIC MEETING: OCTOBER 23rd-27th, 2019

CSACI ABSTRACT GUIDELINES

Submission Deadline: Friday, June 28th, 2019
NO EXTENSIONS WILL BE ACCEPTED

We welcome abstract submissions from all participants at the Canadian Society of Allergy and Clinical Immunology (CSACI) Annual Scientific Meeting.
To be considered, an abstract must comply with the guidelines set out by the 2019 Abstract Committee.

PLEASE READ THE ENTIRE ABSTRACT GUIDELINES (below) BEFORE SUBMITTING YOUR ABSTRACT and ensure that your abstract conforms to the prescribed format.

If you are not already a CSACI member in one of the following categories: (Fellow in Training, Medical Student Associate, Resident Associate, Scientific Student Associate, or Allied Health) you must complete your application to join the CSACI by June 21, 2019 (delays in submitting a membership application will cause abstracts to be rejected by the system). If eligible to join the CSACI, you will be notified by email when your application is accepted at which time you will be able to submit your abstract.

Submitted abstracts that do not conform to the prescribed format will be rejected.

DISCLOSURE INFORMATION IS REQUIRED FROM ALL AUTHORS AND CO-AUTHORS

  • CONFLICT OF INTEREST STATEMENTS – from the presenting/first author on behalf of all co-authors
  • STATEMENT OF INDUSTRY FUNDING
  • CONSENT TO PUBLISH FOR CASE REPORTS – please contact patients who will be presented in a case report early in your abstract preparation. Consent must be uploaded in order for your abstract to be submitted.

ALL ABSTRACTS MUST ADHERE TO THE ABSTRACT GUIDELINES BELOW


CSACI Poster viewing sessions will be held during the CSACI Annual Scientific Meeting in Montreal.

A CORRESPONDING/PRESENTING AUTHOR MUST BE IDENTIFIED.

All presenting authors must be in attendance at their poster during the poster session. The presenting author must be registered for the CSACI ANNUAL MEETING by the end of August 2019. If registration is not completed by the end of August, the abstract will not be displayed. THE CSACI DOES NOT ASSUME THE COSTS OF ATTENDING THIS MEETING.

All approved abstracts will be published in the Allergy, Asthma & Clinical Immunology (AACI) Journal and posted in the CSACI Meeting App. PLEASE NOTE: ABSTRACTS CANNOT BE PUBLISHED IN THE AACI JOURNAL IF THE FINDINGS HAVE BEEN PREVIOUSLY PUBLISHED.

Abstracts will be made available online on the meeting website at am.csaci.ca or through the CSACI meeting app. Paper copies will be available at a cost of $20.00 if requested when you register for the meeting or on-site.

If an abstract is withdrawn, notification must be made in writing on or before Friday, July 28, 2019.

IMPORTANT DATES TO REMEMBER

Friday, June 28, 2019 – Abstract submission deadline

Early August 2019 – Abstract acceptance notices will be sent by email with poster information and presentation date

End of August 2019 – Abstract presenting author should be registered for the CSACI conference

Abstract acceptance notices will be sent by email with presentation date and scheduled assignment

The CSACI Abstract Competition and Oral Presentations are open to CSACI Postdoctoral fellows, Graduate Students, Undergraduate Students, Allergy Fellows-in-Training, Residents, Medical Students and Allied Health Professionals. The goal of these sessions is to highlight the accomplishments of CSACI In-training attendees and Allied Health Professionals.

Abstracts will be judged on scientific content, interest, and relevance to:
(1) Allergic Rhinitis/Asthma; (2) Immunology; (3) Food Allergy/Anaphylaxis; (4) Urticaria/Angioedema; (5) Other Allergy/Immunology; (6) Case Reports; (7) Allied Health;
The CSACI will award prizes for the top poster/presentation in these seven abstract categories.

CSACI Fellows/Faculty, Practicing Allergists, Investigators or Corporate sponsors are encouraged to submit abstracts but are not eligible to participate in the competition.

FOR CSACI RELATED QUESTIONS:

Please contact the CSACI at: info@csaci.ca

CSACI Guidelines for Authors: Preparation of Abstracts

PLEASE NOTE, IF THE ABSTRACT GUIDELINES ARE NOT FOLLOWED,
YOUR SUBMISSION WILL NOT BE ACCEPTED

General Guidelines

Abstracts must be submitted in English.

All abstracts must be submitted via the Abstract Submission Form MS Word format, Max 300 words (Font 10 – Times New Roman) by Friday, June 28, 2019.

Title

The title should be in bold and in sentence case, with no unnecessary capitalization and no full stop at the end (e.g., Results from experiments in this field)

Authors

First name, middle initials if required, and surname with no full stop at the end. Underline the name of the corresponding author. A comma should separate author names. If authors are from different institutions, the appropriate institution number from the affiliation list should be given as a superscript number immediately after each author's name, e.g.:

John Smith1, Susan B Jones2, Bill Fisher3

If the authors are presenting an abstract on behalf of a study group, this information should not be included in the author list, but should appear in an Acknowledgements section.

Affiliations

Affiliations should include department, institute, town, province, and country. Where there are multiple affiliations, each should be listed as a separate paragraph. Each institute should appear in the order used for the author names (see above paragraph) and show the appropriate superscript number, e.g.:
1 Department, University, Town, Province, Canada
2 University, Town, Province, Canada
3 Company, Town, Province, Canada

*Include Email address of corresponding author

Main text

  • Should not exceed 300 words, including tables and references.
  • Use single line spacing.
  • Type the text unjustified, without hyphenating words at line breaks.
  • Use hard returns only to end headings and paragraphs, not to rearrange lines.
  • Use reference format (see example below).
  • Greek and other special characters may be included. If you are unable to reproduce a particular special character, please type out the name of the symbol in full.
  • SI units should be used throughout (litre and molar are permitted).
  • Web links (URLs) should be provided in full, including both the title of the site and the URL, in the following format: Mouse Tumour Biology Database [http://tumor.informatics.jax.org/cancer_links.htm].

  • Abbreviations should be used as sparingly as possible and should be defined when first used.
  • Abstracts should be structured to include a Background, Methods, Results and Conclusions section (with the exception of case reports as shown below).
  • Paragraph headings should be typed in bold with no colon at the end. Do not use the heading ‘Abstract’. Each heading should be in a separate paragraph, e.g.:
    • Background
      Followed by regular text, on a new line and in the same format as listed above for main text.
    • Methods
    • Results
    • Conclusions
    • References (if applicable)
  • Case report abstracts should be structured as follows
    • Background
      Followed by regular text, on a new line and in the same format as listed above for main text.
    • Case presentation
    • Conclusions

NO TABLES OR FIGURES WILL BE ACCEPTED.

References

References may be included if they are essential, but will be included in the abstract word count. All references should be cited consecutively in the text, using numbers in square brackets. Only papers that have been published, or are in press, or are available through public e-print/preprint servers should be included in the reference list. Journal abbreviations should follow MEDLINE standards. References should be laid out at the end of the abstract in Vancouver style and preceded by the relevant reference number. An example of a reference for a journal article follows. The full reference style guide can be found at the journal’s website.

Citations to references should be included in square brackets [1,2].

References

  1. Last name A, Last name B, Last name C: Title of journal article. Journal Medline abbreviation year, Vol: first page-last page.
  2. Last name E: Title of book chapter. In Name of Book. Volume 2. 2nd edition. Edited by Last name F. Place: Publisher; year first page-last page.

e.g.
1. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol- chloroform extraction. Anal Biochem. 1987; 162:156-159.

Abstract Publication

Approved abstracts will be posted in the CSACI Meeting App and published in the AACI Journal.

Please note, in order to avoid copyright infringement, we cannot publish previously published abstracts in our online Journal when a different journal already holds the copyright (e.g. Journal of Allergy and Clinical Immunology for abstracts presented at the annual AAAAI meeting) without permission from the copyright holder.

Trial registration

BioMed Central supports prospective registration of randomized controlled clinical trials. Abstracts related to RCTs should include the trial registry along with the unique identifying number. Trial registers that currently meet our requirements can be found at http://www.icmje.org/about-icmje/faqs/clinical-trials-registration/.

IMPORTANT - Consent to publish

If the abstract contains details relating to individual participants (for example a case report), written informed consent for the publication of these details must be obtained from the participants and a statement to this effect should appear at the end of the abstract.

Our guidelines for consent statements can be found here: https://www.biomedcentral.com/getpublished/editorial-policies#ethics+and+consent.

If the patient is deceased, consent for publication should be obtained from the next of kin. If the patient is under 18, consent should be obtained from the parent or guardian.

Sample Abstract

Epigenetic upregulation of B1–syntrophin correlates with rhinitis symptoms in the Environmental Exposure Unit (EEU)

Michelle L. North 1,3, Lucia Lam 2, Sarah Mah 2, Sarah M. A. Neumann 2, Lisa M. Steacy 3, Alexander Gregor 1, Michael S. Kobor 2,4, and Anne K. Ellis MD 1,3

1 Department of Biomedical & Molecular Sciences and Division of Allergy & Immunology, Department of Medicine, Queen’s University, Kingston, Ontario, Canada.
2 Child & Family Research Institute and Centre for Molecular Medicine & Therapeutics, Vancouver, British Columbia, Canada.
3 Allergy Research Unit, Kingston General Hospital, Kingston, Ontario, Canada.
4 Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.

Background
The role for epigenetics in mediating allergic rhinitis is not well understood. We examined baseline differences in DNA methylation in those with grass-induced allergic rhinitis and changes incited by grass pollen exposure in the Environmental Exposure Unit (EEU). We sought to investigate epigenetic changes that mediate the allergic response in lymphocyte-enriched peripheral blood mononuclear cells.

Methods
15 participants with allergic rhinitis and 8 non-allergic controls were exposed to grass pollen for 3H on two consecutive days. Blood was collected at baseline, 3H and 27H. Peripheral blood mononuclear cells were enriched for lymphocytes using a Lymphoprep gradient. Baseline and 3H samples were interrogated using the Infinium Methylation 450K BeadArray (Illumina). DNA methylation was compared in atopics and controls before and after allergen exposure. Changes in methylation were validated using bisulfite pyrosequencing and mRNA expression was interrogated by qPCR.

Results
10 methylation sites changed significantly between baseline and 3H in the allergic participants. Decreased methylation in the promoter of β1-syntrophin was found to correlate most strongly with symptoms of allergic rhinitis and thus was targeted for further analyses. Bisulfite pyrosequencing confirmed that methylation at the β1-syntrophin promoter correlated directly with allergic rhinitis symptoms. qPCR revealed β1-syntrophin expression correlated with methylation at the promoter and with symptom scores upon grass pollen exposure.

Conclusion
Grass allergy sufferers undergo rapid changes in DNA methylation upon allergen exposure, concurrent with the development of symptoms. This study is the first to identify β1-syntrophin as a gene that undergoes allergen-induced epigenetic modifications leading to expression changes that correlate with allergy symptoms.

References
(If applicable)

Acknowledgements
(If applicable)